GlassScriptPhysician profile
Kevin R Gee
NPI 1710975289
$8,828.21
in general payments reported to CMS, 2019-2025
30 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,043 · 2020: $313 · 2021: $1,475 · 2022: $2,068 · 2023: $646 · 2024: $702 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.84 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,626.09 | 2019-2020 | |
| Teleflex LLC | $1,443.55 | 2021-2025 | Urolift, Barrigel |
| Coloplast Corp | $1,338.54 | 2019-2025 | Speedicath |
| Astellas Pharma US INC | $857.50 | 2019-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $835.08 | 2021-2025 | |
| Urogen Pharma, INC. | $556.76 | 2021-2025 | Jelmyto |
| Pfizer INC. | $414.58 | 2019-2025 | |
| Calyxo, INC. | $309.35 | 2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $199.64 | 2021-2025 | Erleada |
| Bioprotect Medical, INC. | $171.57 | 2024-2025 | Bioprotect Balloon Implant System |
| Sumitomo Pharma America, INC. | $133.25 | 2023-2025 | Orgovyx, Gemtesa |
| Stryker Corporation | $128.51 | 2024 | 1788, Infinity, Aim (Advanced Imaging Modality) |
| Boston Scientific Corporation | $99.35 | 2019-2025 | General - Erectile Dysfunction |
| Tolmar, INC. | $89.76 | 2023-2025 | Eligard, Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $88.32 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $86.47 | 2019-2024 | Aveed, Xiaflex |
| Olympus America INC. | $80.61 | 2021-2025 | Itind System |
| Ferring Pharmaceuticals INC. | $57.74 | 2019 | |
| Rochester Medical Corporation | $54.87 | 2021-2022 | |
| Endo USA, INC. | $45.74 | 2025 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $44.91 | 2022-2024 | Prolaris |
| Antares Pharma, INC. | $30.43 | 2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $22.90 | 2024 | |
| Abbvie INC. | $20.75 | 2023 | |
| Becton, Dickinson and Company | $18.82 | 2025 | Magic3 Intermittent Catheter |
| Novartis Pharmaceuticals Corporation | $16.58 | 2025 | |
| Metuchen Pharmaceuticals | $16.00 | 2019 | |
| Urovant Sciences INC | $15.01 | 2022 | |
| Cook Medical LLC | $13.82 | 2021 | |
| Allergan, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.